首页> 外文会议>European Meeting on Supercritical Fluids Reactions, Materials and Natural Products Processing >CONSTRUCTION OF A PHASE DIAGRAM FOR ITRACONAZOLE/EC 20 CPS SOLID DISPERSIONS PREPARED BY HOT STAGE EXTRUSION WITH AND WITHOUT INJECTION OF PRESSURIZED CO_2
【24h】

CONSTRUCTION OF A PHASE DIAGRAM FOR ITRACONAZOLE/EC 20 CPS SOLID DISPERSIONS PREPARED BY HOT STAGE EXTRUSION WITH AND WITHOUT INJECTION OF PRESSURIZED CO_2

机译:用热级挤出制备的伊唑唑/ EC 20 CPS固体分散体的构建型号,无需注入加压CO_2

获取原文

摘要

Although a significant number of pharmaceutical examples of hot stage extrusion have been described in literature [1, 2], one of the major drawbacks of hot stage extrusion is its limited applicability to thermally stable products. For a number of active substances (and excipients), hot stage extrusion cannot be used due to thermal degradation and subsequent loss of its activity [3]. In these cases, a plasticizer can be added in order to reduce the viscosity of the mixture in the extruder and therefore to lower the process temperature settings. However, added plasticizers usually remain in the product, thus affecting its properties and performance. Typically, conventional plasticizers such as triacetin or polyethylene glycol are used in a concentration range of 5 up to 30 wt% of the extrudable mass [4-6]. Therefore, it is beneficial to have a temporary plasticizer that lowers the processing temperature during hot stage extrusion without being present in the final formulation. Previous work has shown that pressurized carbon dioxide, when injected during hot stage extrusion, worked as a temporary plasticizer for a number of pharmaceutically acceptable polymers, including PVP-VA 64, eudragit E100 and EC 20 cps [7]. Verreck et al. also describe the injection of carbon dioxide during hot stage extrusion of itraconazole with PVPVA 64 and itraconazole with EC 20 cps and confirm the plasticization of the product by pressurized carbon dioxide [8,9]. To better understand the solid dispersion, a phase diagram of itraconazole and EC 20 cps was constructed using hot stage extrusion with and without CO_2 injection.
机译:尽管在文献[1,2]中已经描述了大量的热级挤出的药物实例,但热阶段挤出的主要缺点之一是其对热稳定产品的适用性有限。对于许多活性物质(和赋形剂),由于热降解和随后的活性损失,不能使用热级挤出[3]。在这些情况下,可以添加增塑剂以减少挤出机中混合物的粘度,从而降低工艺温度设置。然而,添加的增塑剂通常保留在产品中,从而影响其性能和性能。通常,诸如三循环素或聚乙二醇的常规增塑剂用于5至30wt%的可挤出质量的浓度范围[4-6]。因此,具有临时增塑剂是有益的,可在热阶段挤出期间降低加工温度而不存在于最终配方中。先前的工作表明,加压二氧化碳当在热阶段挤出期间注射时,作为许多药学上可接受的聚合物的临时增塑剂,包括PVP-VA 64,Eudragit E100和EC 20 CPS [7]。 verreck等。还描述了用PVPVA 64和Itraconazole的热阶段挤出期间注射二氧化碳,用PVPVA 64和Itraconazole,通过加压二氧化碳确认产品的塑化[8,9]。为了更好地理解固体分散体,使用热级挤出和不含CO_2注射的热级挤出构建伊唑康唑和EC 20cps的相图。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号